west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "陈有信" 45 results
  • Polypoidal choroidal vasculopathy: a controversial disease identity with challenges and opportunities

    The pathogenesis of polypoidal choroidal vasculopathy (PCV) is still controversial. More evidence of clinical and basic research is needed to distinguish PCV from an independent disease to a subtype of age-related macular degeneration. Not only that, there are also many puzzles in the diagnosis, treatment options and prognosis of PCV. In addition to these common problems, we also face a large population with risk factors, a large number of PCV patients with multiple and complex challenges in China. There is a long way to go to reduce the damage effects of PCV on visual function. To fulfil this goal, we need make full use of the huge resources of PCV patients and turn these challenges into opportunities, and contribute the improvement of diagnosis and better understanding of PCV pathogenesis.

    Release date: Export PDF Favorites Scan
  • 生命不息耕耘不止——记中国医学科学院北京协和医院眼科张承芬教授

    Release date: Export PDF Favorites Scan
  • 脉络膜新生血管治疗研究展望

    Release date:2016-09-02 05:48 Export PDF Favorites Scan
  • Research progress of optical coherence tomography angiography in retinal vein occlusion

    Retinal vein occlusion (RVO) is a vascular disease characterized by intraretinal hemorrhage, edema and hard exudation, which is caused by increased retinal vein pressure. OCT angiography (OCTA) has been widely used in the diagnosis of retinal vascular diseases including RVO by virtue of non-invasive, high resolution and stratified display of superficial, deep retinal vessels and quantification of retinal vessel density and non-perfusion area size. OCTA can provide information of retinal microvascular structure and blood perfusion under the condition of disease, it also can be used to evaluate the effect of treatment and changes of retinal circulation during the course of disease follow-up. Although OCTA cannot replace fundus angiography completely, it has brought us more information about the pathogenesis, disease progression and prognostic factors of RVO. It is believed that with the progress of technology, OCTA will bring us a new chapter in the study of retinal vascular diseases including RVO.

    Release date:2019-07-16 05:35 Export PDF Favorites Scan
  • 息肉样脉络膜血管病变伴视网膜色素上皮撕裂的临床特征

    Release date: Export PDF Favorites Scan
  • 视网膜血管疾病的光相干断层扫描检查图像解读

    糖尿病视网膜病变、视网膜动静脉血管阻塞等视网膜血管疾病光相干断层扫描(OCT)检查可以发现视网膜出血、渗出、玻璃体视网膜界面异常等图像特征;了解其光感受器细胞受损程度。正确认识视网膜血管疾病的OCT图像特征,探讨其形成机制的组织学基础,有助于加深对视网膜血管疾病发生发展转归过程的了解,对视网膜血管疾病诊断、预后判断和提高临床治疗效果具有重要意义。

    Release date:2016-09-02 05:26 Export PDF Favorites Scan
  • Fundus autofluorescence and its applications in retinal diseases

    Autofluorescence is produced by lipofuscin in retinal pigment epithelium (RPE) cells which is induced by exciting light and enables the visualization of lipofuscin changes in the RPE cells, thus showing the function of RPE and photoreceptor cells. Fundus autofluorescence (FAF) imaging is a non-invasive imaging technique providing information of RPE and photoreceptor cells, which is not obtainable with other imaging modalities. The scope of applications includes identification of diseased RPE in retinal diseases, elucidating pathophysiological mechanisms, estimating disease progression and prognosis, guiding treatment protocols. Common fundus diseases have different pathological types, levels and causes, so they can cause various damages of RPE and photoreceptor cells which induce complicated FAF. It is worth to further observing and investigating the common retinal diseases' FAF characteristics and clinical applications.

    Release date: Export PDF Favorites Scan
  • 开展吲哚青绿脉络膜血管造影研究,提高眼底病临床诊治和研究水平

    Release date:2016-09-02 06:11 Export PDF Favorites Scan
  • 从医五十载 耕耘仍不休——张承芬教授传略

    Release date:2016-09-02 06:01 Export PDF Favorites Scan
  • 新一代抗血管内皮生长因子药物阿柏西普基础及临床研究现状

    血管内皮生长因子(VEGF)是新生血管性及血管性眼底疾病的重要治疗靶点。阿柏西普(Aflibercept,眼用制药VEGF Trap-Eye,商品名Eylea)是继哌加他尼钠(Pegaptanib,商品名Macugen)、雷珠单抗(Ranibizumab,商品名Lucentis)之后的新一代抗VEGF药物,可直接或间接作用于VEGF家族所有成员,减少新生血管形成,降低血管通透性。VEGF Trap-Eye尤与VEGF-A亲和力高,作用时间持久,在临床前实验中展现出较好的抗新生血管作用和降低血管通透性作用;玻璃体腔注射治疗老年性黄斑变性可取得与Ranibizumab相似的疗效,且延长注射间隔并不降低疗效;治疗糖尿病黄斑水肿疗效明显优于激光光凝治疗,且不同给药间隔可取得相似疗效;在提高视网膜静脉阻塞患者视力和减轻水肿方面亦有一定作用。用于治疗病理性近视继发脉络膜新生血管等其他疾病的疗效尚在临床观察中。VEGF Trap-Eye治疗新生血管性及血管性眼底疾病要进一步全面评价有效性和安全性还需要进行更长期的临床观察。

    Release date:2016-09-02 05:21 Export PDF Favorites Scan
5 pages Previous 1 2 3 4 5 Next

Format

Content